Plain-English translation of NCT06617936 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether tislelizumab, combined with two other medications, can help people with advanced lung cancer that cannot currently be surgically removed. The goal is to shrink the tumors with these medications before surgery, potentially making surgery possible where it wasn't before. After surgery, participants would continue receiving the medication to help prevent the cancer from returning.
Many people with stage III lung cancer have tumors that are too large or in locations where surgery is too risky to perform safely. This trial is designed to find out whether the new treatment combination can shrink these tumors enough to make surgery a safe option, which could improve survival and cure rates.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combination as injections and infusions once every three weeks for up to 4 cycles (about 12 weeks) before any potential surgery. Doctors will then evaluate whether the tumors have shrunk enough to be surgically removed. If surgery is possible, you would have the operation 4 to 6 weeks after finishing the initial treatment, then continue receiving the medication for up to one year afterward. You will have regular blood tests, scans, and clinic visits throughout the trial to monitor how well the treatment is working and for any side effects.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
China